These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
926 related articles for article (PubMed ID: 37044040)
1. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents. Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040 [TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186 [TBL] [Abstract][Full Text] [Related]
3. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters. Zhang XS; Windau A; Meyers J; Yang X; Dong F Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540 [TBL] [Abstract][Full Text] [Related]
5. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903 [TBL] [Abstract][Full Text] [Related]
6. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
7. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster. Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines. Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514 [TBL] [Abstract][Full Text] [Related]
9. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434 [TBL] [Abstract][Full Text] [Related]
10. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426 [TBL] [Abstract][Full Text] [Related]
11. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583 [TBL] [Abstract][Full Text] [Related]
13. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination. Yoo J; Kim Y; Cha YM; Lee J; Jeong YJ; Kim SH; Maragakis LL; Lee S J Infect Public Health; 2023 Oct; 16(10):1537-1543. PubMed ID: 37562081 [TBL] [Abstract][Full Text] [Related]
14. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897 [TBL] [Abstract][Full Text] [Related]
15. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination. Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay. Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S Front Immunol; 2022; 13():1039163. PubMed ID: 36505453 [TBL] [Abstract][Full Text] [Related]
18. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Munoz FM; Posavad CM; Richardson BA; Badell ML; Bunge KE; Mulligan MJ; Parameswaran L; Kelly CW; Olson-Chen C; Novak RM; Brady RC; Pasetti MF; Defranco EA; Gerber JS; Shriver MC; Suthar MS; Coler RN; Berube BJ; Kim SH; Piper JM; Miller AM; Cardemil CV; Neuzil KM; Beigi RH; Vaccine; 2023 Aug; 41(36):5296-5303. PubMed ID: 37451878 [TBL] [Abstract][Full Text] [Related]
20. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH; Saini M; Wieland A; Manning KE; Ellis M; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Edara VV; Patel M; Steur C; Nooka AK; Green F; Johns MA; O'Brein F; Shanmugasundaram U; Zarnitsyna VI; Ahmed H; Nyhoff LE; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar MS; Dhodapkar MV; Ramalingam S; Ahmed R J Clin Oncol; 2022 Nov; 40(33):3808-3816. PubMed ID: 35759727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]